| For: | Reshetnyak VI, Maev IV. Bile acid therapy for primary biliary cholangitis: Pathogenetic validation. World J Exp Med 2025; 15(1): 101771 [PMID: 40115760 DOI: 10.5493/wjem.v15.i1.101771] |
|---|---|
| URL: | https://www.wjgnet.com/2308-3840/full/v15/i1/101771.htm |
| Number | Citing Articles |
| 1 |
Guanyi He, Jie Qing. Bile Acid-Mediated Interactions with Various Cell Types in the Cholestatic Liver. DNA and Cell Biology 2025; 44(9): 502 doi: 10.1177/10445498251359370
|
| 2 |
Kun Yang, Bingqing Yang, Jiamin Chen, Lili Gao, Xiaoyi Han, Junke Hu, Liang Zhang, Xiangmei Chen, Qi Wang, Xingang Zhou, Ting Liu, Xuefei Duan, Lei Sun. Clinicopathological features of hepatobiliary cells in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid. BMC Gastroenterology 2026; doi: 10.1186/s12876-026-04686-9
|
| 3 |
Vasiliy Ivanovich Reshetnyak, Elena Vladimirovna Vinnitskaya, Igor Veniaminovich Maev. Primary biliary cholangitis: A historical perspective from xanthomatous lesions to modern molecular biology. World Journal of Gastrointestinal Pathophysiology 2025; 16(2): 107347 doi: 10.4291/wjgp.v16.i2.107347
|
